213 related articles for article (PubMed ID: 21854342)
1. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
Skoner DP; Meltzer EO; Milgrom H; Stryszak P; Teper A; Staudinger H
J Asthma; 2011 Oct; 48(8):848-59. PubMed ID: 21854342
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
[TBL] [Abstract][Full Text] [Related]
3. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG
Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
[TBL] [Abstract][Full Text] [Related]
4. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma.
Karpel JP; Busse WW; Noonan MJ; Monahan ME; Lutsky B; Staudinger H
Ann Pharmacother; 2005 Dec; 39(12):1977-83. PubMed ID: 16264062
[TBL] [Abstract][Full Text] [Related]
5. Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler.
Zetterström O; Dahl R; Lindqvist A; Olsson P
Respir Med; 2008 Oct; 102(10):1406-11. PubMed ID: 18640826
[TBL] [Abstract][Full Text] [Related]
6. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
Kemp JP; Berkowitz RB; Miller SD; Murray JJ; Nolop K; Harrison JE
J Allergy Clin Immunol; 2000 Sep; 106(3):485-92. PubMed ID: 10984368
[TBL] [Abstract][Full Text] [Related]
7. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.
Nayak AS; Banov C; Corren J; Feinstein BK; Floreani A; Friedman BF; Goldsobel A; Gottschlich GM; Hannaway PJ; Lampl KL; Lapidus RJ; Lawrence M; Lumry W; Munk Z; Pearlman D; Scardella AT; Schenkel EJ; Segal AT; Segall N; Silverman B; Shneyer L; Nolop KB; Harrison JE
Ann Allergy Asthma Immunol; 2000 Apr; 84(4):417-24. PubMed ID: 10795650
[TBL] [Abstract][Full Text] [Related]
8. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
Noonan M; Karpel JP; Bensch GW; Ramsdell JW; Webb DR; Nolop KB; Lutsky BN
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):36-43. PubMed ID: 11206236
[TBL] [Abstract][Full Text] [Related]
9. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
[TBL] [Abstract][Full Text] [Related]
10. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma.
Zeidler M; Corren J; Tashkin DP
Curr Med Res Opin; 2010 Jun; 26(6):1295-305. PubMed ID: 20370376
[TBL] [Abstract][Full Text] [Related]
11. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.
Kosoglou T; Cutler DL; Staudinger H; Herron JM
Chest; 2010 Jan; 137(1):115-21. PubMed ID: 19749003
[TBL] [Abstract][Full Text] [Related]
12. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma.
Skoner DP; Gentile DA; Angelini B
Allergy Asthma Proc; 2010; 31(1):10-9. PubMed ID: 20167141
[TBL] [Abstract][Full Text] [Related]
13. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma.
Corren J; Berkowitz R; Murray JJ; Prenner B
Int J Clin Pract; 2003 Sep; 57(7):567-72. PubMed ID: 14529054
[TBL] [Abstract][Full Text] [Related]
14. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
[TBL] [Abstract][Full Text] [Related]
15. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
Berger WE; Milgrom H; Chervinsky P; Noonan M; Weinstein SF; Lutsky BN; Staudinger H
Ann Allergy Asthma Immunol; 2006 Nov; 97(5):672-80. PubMed ID: 17165278
[TBL] [Abstract][Full Text] [Related]
16. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
17. Inhaled mometasone furoate improves health-related quality of life in patients with persistent asthma.
Karpel J; D'urzo A; Lockey RF
J Asthma; 2008 Nov; 45(9):747-53. PubMed ID: 18972289
[TBL] [Abstract][Full Text] [Related]
18. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate.
Nathan RA; Nayak AS; Graft DF; Lawrence M; Picone FJ; Ahmed T; Wolfe J; Vanderwalker ML; Nolop KB; Harrison JE
Ann Allergy Asthma Immunol; 2001 Feb; 86(2):203-10. PubMed ID: 11258691
[TBL] [Abstract][Full Text] [Related]
19. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma.
Holgate ST; Arshad H; Stryszak P; Harrison JE
J Allergy Clin Immunol; 2000 May; 105(5):906-11. PubMed ID: 10808170
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
Noonan M; Leflein J; Corren J; Staudinger H
BMC Pediatr; 2009 Jul; 9():43. PubMed ID: 19594937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]